pioglitazone has been researched along with Atheroma in 11 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This study aimed to determine the effects of a PPAR-g agonist pioglitazone on atherogenesis in an ApoE knockout mouse (ApoE-/-) diabetic mouse model and in a cultured vascular smooth muscle cells (VSMCs) model." | 7.85 | Pioglitazone Attenuates Atherosclerosis in Diabetic Mice by Inhibition of Receptor for Advanced Glycation End-Product (RAGE) Signaling. ( Di, B; Gao, H; Li, H; Li, W; Shen, X, 2017) |
| "Our study suggests that pioglitazone can reduce the number of plaque thrombosis incidences by decreasing plaque inflammation." | 7.81 | Plaque Thrombosis is Reduced by Attenuating Plaque Inflammation with Pioglitazone and is Evaluated by Fluorodeoxyglucose Positron Emission Tomography. ( Lv, SZ; Wang, ZM; Yan, YF; Zhang, MD; Zhang, YH; Zhao, QM; Zhao, XC, 2015) |
| "Thirty rabbits were randomly divided into an atherosclerosis group, an atorvastatin group, and an atorvastatin plus pioglitazone group." | 4.12 | Pioglitazone combined with atorvastatin promotes plaque stabilization in a rabbit model. ( Chen, X; Liang, Z; Nie, M; Yan, Y; Zhang, X; Zhao, Q, 2022) |
| " This study aimed to determine the effects of a PPAR-g agonist pioglitazone on atherogenesis in an ApoE knockout mouse (ApoE-/-) diabetic mouse model and in a cultured vascular smooth muscle cells (VSMCs) model." | 3.85 | Pioglitazone Attenuates Atherosclerosis in Diabetic Mice by Inhibition of Receptor for Advanced Glycation End-Product (RAGE) Signaling. ( Di, B; Gao, H; Li, H; Li, W; Shen, X, 2017) |
| "Our study suggests that pioglitazone can reduce the number of plaque thrombosis incidences by decreasing plaque inflammation." | 3.81 | Plaque Thrombosis is Reduced by Attenuating Plaque Inflammation with Pioglitazone and is Evaluated by Fluorodeoxyglucose Positron Emission Tomography. ( Lv, SZ; Wang, ZM; Yan, YF; Zhang, MD; Zhang, YH; Zhao, QM; Zhao, XC, 2015) |
| "8." | 2.77 | Pioglitazone induces regression and stabilization of coronary atherosclerotic plaques in patients with impaired glucose tolerance. ( Du, YY; Wang, XF; Yang, HB; Zhang, JY; Zhao, XY, 2012) |
| "Treatment with pioglitazone may offer a new effect on the whole vessel wall, promoting the stability of advanced atherosclerotic plaques." | 1.48 | Vascular dysfunction elicited by a cross talk between periaortic adipose tissue and the vascular wall is reversed by pioglitazone. ( Cannizzo, B; Castro, C; Cejas, J; García, R; Quesada, I; Redondo, A, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (90.91) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, X | 1 |
| Chen, X | 1 |
| Liang, Z | 1 |
| Nie, M | 1 |
| Yan, Y | 1 |
| Zhao, Q | 1 |
| Wu, Y | 1 |
| Zhang, Y | 1 |
| Dai, L | 1 |
| Wang, Q | 1 |
| Xue, L | 1 |
| Su, Z | 1 |
| Zhang, C | 1 |
| Gao, H | 1 |
| Li, H | 1 |
| Li, W | 1 |
| Shen, X | 1 |
| Di, B | 1 |
| Quesada, I | 1 |
| Cejas, J | 1 |
| García, R | 1 |
| Cannizzo, B | 1 |
| Redondo, A | 1 |
| Castro, C | 1 |
| Christoph, M | 1 |
| Herold, J | 1 |
| Berg-Holldack, A | 1 |
| Rauwolf, T | 1 |
| Ziemssen, T | 1 |
| Schmeisser, A | 1 |
| Weinert, S | 1 |
| Ebner, B | 1 |
| Said, S | 1 |
| Strasser, RH | 1 |
| Braun-Dullaeus, RC | 1 |
| Zhang, MD | 1 |
| Zhao, XC | 1 |
| Zhang, YH | 1 |
| Yan, YF | 1 |
| Wang, ZM | 1 |
| Lv, SZ | 1 |
| Zhao, QM | 1 |
| Nakashiro, S | 1 |
| Matoba, T | 1 |
| Umezu, R | 1 |
| Koga, J | 1 |
| Tokutome, M | 1 |
| Katsuki, S | 1 |
| Nakano, K | 1 |
| Sunagawa, K | 1 |
| Egashira, K | 1 |
| Császár, A | 1 |
| Yang, HB | 1 |
| Zhao, XY | 1 |
| Zhang, JY | 1 |
| Du, YY | 1 |
| Wang, XF | 1 |
| Chibana, H | 1 |
| Mitsutake, Y | 1 |
| Itaya, N | 1 |
| Ueno, T | 1 |
| Komiyama, N | 1 |
3 reviews available for pioglitazone and Atheroma
| Article | Year |
|---|---|
[Anti-atherosclerotic effect of pioglitazone--the first evidence of the role of triglyceride/HDL ratio].
Topics: Animals; Anti-Inflammatory Agents; Anticholesteremic Agents; Atherosclerosis; Blood Pressure; Body F | 2011 |
[Stabilization of vulnerable coronary plaque].
Topics: Acute Coronary Syndrome; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pioglitazone; Plaqu | 2011 |
[PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) trial].
Topics: Acute Coronary Syndrome; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Plaqu | 2011 |
3 trials available for pioglitazone and Atheroma
| Article | Year |
|---|---|
Effects of the PPARγ agonist pioglitazone on coronary atherosclerotic plaque composition and plaque progression in non-diabetic patients: a double-center, randomized controlled VH-IVUS pilot-trial.
Topics: Acute Coronary Syndrome; Aged; Cardiovascular Agents; Coronary Artery Disease; Coronary Vessels; Dis | 2015 |
Pioglitazone induces regression and stabilization of coronary atherosclerotic plaques in patients with impaired glucose tolerance.
Topics: Adiponectin; C-Reactive Protein; Coronary Vessels; Endothelin-1; Female; Glucose Tolerance Test; Hum | 2012 |
[PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) trial].
Topics: Acute Coronary Syndrome; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Plaqu | 2011 |
6 other studies available for pioglitazone and Atheroma
| Article | Year |
|---|---|
Pioglitazone combined with atorvastatin promotes plaque stabilization in a rabbit model.
Topics: Animals; Atherosclerosis; Atorvastatin; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Matr | 2022 |
An apoptotic body-biomimic liposome in situ upregulates anti-inflammatory macrophages for stabilization of atherosclerotic plaques.
Topics: Animals; Anti-Inflammatory Agents; Apolipoproteins E; Atherosclerosis; Biomimetic Materials; Cytokin | 2019 |
Pioglitazone Attenuates Atherosclerosis in Diabetic Mice by Inhibition of Receptor for Advanced Glycation End-Product (RAGE) Signaling.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Cells, Cultured; Diabetes Complications; Diabetes Melli | 2017 |
Vascular dysfunction elicited by a cross talk between periaortic adipose tissue and the vascular wall is reversed by pioglitazone.
Topics: Adipose Tissue; Animals; Aorta; Apolipoproteins E; Blood Glucose; Blood Vessels; Fructose; Hypoglyce | 2018 |
Plaque Thrombosis is Reduced by Attenuating Plaque Inflammation with Pioglitazone and is Evaluated by Fluorodeoxyglucose Positron Emission Tomography.
Topics: Animals; Biomarkers; Blood Glucose; C-Reactive Protein; Fluorodeoxyglucose F18; Hypoglycemic Agents; | 2015 |
Pioglitazone-Incorporated Nanoparticles Prevent Plaque Destabilization and Rupture by Regulating Monocyte/Macrophage Differentiation in ApoE-/- Mice.
Topics: Administration, Intravenous; Angiotensin II; Animals; Apolipoproteins E; Atherosclerosis; Brachiocep | 2016 |